• LAST PRICE
    41.9500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    40.1000/ 1
  • Ask / Lots
    42.6700/ 2
  • Open / Previous Close
    0.0000 / 41.9500
  • Day Range
    ---
  • 52 Week Range
    Low 27.3600
    High 47.7500
  • Volume
    569
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeSAGE
Data delayed at least 15 minutes.

Industry Peers

Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSAGE
SAGE Therapeutics Inc
2.5B
-4.9x
---
United StatesXENE
Xenon Pharmaceuticals Inc
2.3B
-23.0x
---
United StatesEQRX
EQRx Inc
2.8B
0.0x
---
United StatesROIV
Roivant Sciences Ltd
2.7B
-3.0x
---
United StatesRLAY
Relay Therapeutics Inc
2.1B
-7.6x
---
United StatesALLO
Allogene Therapeutics Inc
2.2B
-7.0x
---
As of 2022-08-08

Company Information

Sage Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. It has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. It targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. It has a portfolio of other compounds that target GABAA receptors, including SAGE-324.

Contact Information

Headquarters
215 1st StCAMBRIDGE, MA, United States 02142-1213
Phone
617-299-8380
Fax
617-299-8379

Executives

Non-Executive Independent Chairman of the Board
Kevin Starr
President, Chief Executive Officer, Director
Barry Greene
Chief Financial Officer, Treasurer
Kimi Iguchi
Senior Vice President, General Counsel, Corporate Secretary
Anne Cook
Chief Scientific Officer
Albert Robichaud

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
---
Revenue (TTM)
---
Shares Outstanding
---
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
---
Book Value
---
P/E Ratio
-4.9x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.